health-austrade-logo.gif
   
Search     Click to Search
   
health-nav-health-over.gifhealth-nav-bio-over.gifhealth-nav-wellbeing-over.gif














Email Us
Enquiry form

University of Western Australia

University of Western Australia
 

Overview

UWA’s office of Industry and Innovation (OII) manages the technology transfer of research findings and interfaces with pharmaceutical and biotechnology companies to commercialise UWA technology and to engage with industry on research contracts. Current project areas include cancer therapies and diagnostics, orthopaedics, neuroregeneration, Alzheimer’s Disease, stem cell research and agriculture and aquaculture feed materials.

OII has a track record in commercialising biotechnology. Examples include:

  • Biotechnology Start-up Companies
  • Resonance Health Limited
  • Alzhyme Pty Ltd - developing Alzheimer's Disease therapeutics

Biomedical licenses

OII has negotiated licences with the following companies:

  • Dimerix
  • Dupont
  • BioPharmica
  • Fournier
  • UpState
  • Epigenomics AG
  • Ceutica
  • Verigen

Research contracts

UWA carries out research and clinical trials for national and international pharmaceutical and biotechnology partners. Some recent examples include:

  • Johnson & Johnson
  • GlaxoSmithKline
  • Fujirebio
  • Medela AG
  • Novartis
  • Pfizer
  • Smith & Nephew
  • Solbec


Business Opportunities (i.e Corporate Alliances/Partnerships)

UWA is seeking partners to license technologies; to collaboratively develop early stage R&D opportunities; to invest in strategic research programs and to fund sponsored research.

Technology/Products and Services Description

  • Ang001 – an angiogenesis inhibitor that has been shown to restrict ovarian cancer development in nude mice
  • SLIRP – a therapeutic target and diagnostic marker for hormone dependent cancers
  • ZX1 – a protein that can result in bone formation and is a potential treatment for osteoporosis
  • Tau phosphorylator – an enzyme with a unique role in the phosphorylation of Tau; potential target for development of a treatment for Alzheimer’s disease
  • Protein thiol assay – a “2-tag” approach for measuring protein thiolynation
  • Rett treatment – a potential treatment for Rett syndrome and other pervasive development disorders

Competitive Advantages

Access to world class research facilities and a wide range of research expertise.

Website address: www.oii.uwa.edu.au


Health button - Request introduction     Health button - Back to Health B2B Portal

     

Austrade website | DFAT | Minister for TradePrivacy disclaimer | Technical info | Site disclaimer | Linking policy